P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments (2024)

Zalewski, N. L., Lennon, V. A., Lachance, D. H., Klein, C. J., Pittock, S. J. (2016). P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. Muscle and Nerve, 54(2), 220-227. https://doi.org/10.1002/mus.25027

P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. / Zalewski, Nicholas L.; Lennon, Vanda A.; Lachance, Daniel H. et al.
In: Muscle and Nerve, Vol. 54, No. 2, 01.08.2016, p. 220-227.

Research output: Contribution to journal › Article › peer-review

Zalewski, NL, Lennon, VA, Lachance, DH, Klein, CJ, Pittock, SJ 2016, 'P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments', Muscle and Nerve, vol. 54, no. 2, pp. 220-227. https://doi.org/10.1002/mus.25027

Zalewski NL, Lennon VA, Lachance DH, Klein CJ, Pittock SJ, Mckeon A. P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. Muscle and Nerve. 2016 Aug 1;54(2):220-227. doi: 10.1002/mus.25027

Zalewski, Nicholas L. ; Lennon, Vanda A. ; Lachance, Daniel H. et al. / P/Q- and N-type calcium-channel antibodies : Oncological, neurological, and serological accompaniments. In: Muscle and Nerve. 2016 ; Vol. 54, No. 2. pp. 220-227.

@article{0c50a3bc53c24289992b9dc0d509eccf,

title = "P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments",

abstract = "Introduction: Voltage-gated calcium-channel autoimmunity (VGCC-P/Q and VGCC-N types) occurs beyond Lambert–Eaton syndrome and lung cancer. Methods: We reviewed records for 236 Mayo Clinic patients with VGCC antibodies found in evaluation for paraneoplastic neurological autoimmunity (generally without myasthenic syndromes). Results: VGCC autoantibodies were detected in 3.4% of neurological patients, 1.7% of healthy controls, and 4% of neurologically asymptomatic lung cancer controls. Fifty neurological patients (21%) had ≥ 1 neoplasm, historically (46) or detected prospectively [small-cell lung carcinoma (2), breast adenocarcinoma (2), lymphoma (1), and suspected tonsillar carcinoma (1)]. Autoimmune neurological diagnosis frequencies (encephalopathy, ataxia, myelopathy, neuropathy, neuromuscular junction disorder, and myopathy) among patients with medium values (24%; 0.10–0.99 nmol/L) or low values (19%; 0.03–0.10 nmol/L) were fewer than among patients with antibody values exceeding 1.00 nmol/L (71%; P = 0.02 and 0.004, respectively). Conclusions: Among neuronal VGCC-autoantibody–seropositive patients, autoimmune neurological phenotypes and cancer types are diverse. Cautious interpretation of results (particularly medium and low values) is advised. Muscle Nerve, 2016 Muscle Nerve 54: 220–227, 2016.",

keywords = "ataxia, calcium channel, myasthenia, neuropathy, paraneoplastic",

author = "Zalewski, {Nicholas L.} and Lennon, {Vanda A.} and Lachance, {Daniel H.} and Klein, {Christopher J.} and Pittock, {Sean J.} and Andrew Mckeon",

note = "Publisher Copyright: {\textcopyright} 2016 Wiley Periodicals, Inc.",

year = "2016",

month = aug,

day = "1",

doi = "10.1002/mus.25027",

language = "English (US)",

volume = "54",

pages = "220--227",

journal = "Muscle and Nerve",

issn = "0148-639X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - P/Q- and N-type calcium-channel antibodies

T2 - Oncological, neurological, and serological accompaniments

AU - Zalewski, Nicholas L.

AU - Lennon, Vanda A.

AU - Lachance, Daniel H.

AU - Klein, Christopher J.

AU - Pittock, Sean J.

AU - Mckeon, Andrew

N1 - Publisher Copyright:© 2016 Wiley Periodicals, Inc.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Introduction: Voltage-gated calcium-channel autoimmunity (VGCC-P/Q and VGCC-N types) occurs beyond Lambert–Eaton syndrome and lung cancer. Methods: We reviewed records for 236 Mayo Clinic patients with VGCC antibodies found in evaluation for paraneoplastic neurological autoimmunity (generally without myasthenic syndromes). Results: VGCC autoantibodies were detected in 3.4% of neurological patients, 1.7% of healthy controls, and 4% of neurologically asymptomatic lung cancer controls. Fifty neurological patients (21%) had ≥ 1 neoplasm, historically (46) or detected prospectively [small-cell lung carcinoma (2), breast adenocarcinoma (2), lymphoma (1), and suspected tonsillar carcinoma (1)]. Autoimmune neurological diagnosis frequencies (encephalopathy, ataxia, myelopathy, neuropathy, neuromuscular junction disorder, and myopathy) among patients with medium values (24%; 0.10–0.99 nmol/L) or low values (19%; 0.03–0.10 nmol/L) were fewer than among patients with antibody values exceeding 1.00 nmol/L (71%; P = 0.02 and 0.004, respectively). Conclusions: Among neuronal VGCC-autoantibody–seropositive patients, autoimmune neurological phenotypes and cancer types are diverse. Cautious interpretation of results (particularly medium and low values) is advised. Muscle Nerve, 2016 Muscle Nerve 54: 220–227, 2016.

AB - Introduction: Voltage-gated calcium-channel autoimmunity (VGCC-P/Q and VGCC-N types) occurs beyond Lambert–Eaton syndrome and lung cancer. Methods: We reviewed records for 236 Mayo Clinic patients with VGCC antibodies found in evaluation for paraneoplastic neurological autoimmunity (generally without myasthenic syndromes). Results: VGCC autoantibodies were detected in 3.4% of neurological patients, 1.7% of healthy controls, and 4% of neurologically asymptomatic lung cancer controls. Fifty neurological patients (21%) had ≥ 1 neoplasm, historically (46) or detected prospectively [small-cell lung carcinoma (2), breast adenocarcinoma (2), lymphoma (1), and suspected tonsillar carcinoma (1)]. Autoimmune neurological diagnosis frequencies (encephalopathy, ataxia, myelopathy, neuropathy, neuromuscular junction disorder, and myopathy) among patients with medium values (24%; 0.10–0.99 nmol/L) or low values (19%; 0.03–0.10 nmol/L) were fewer than among patients with antibody values exceeding 1.00 nmol/L (71%; P = 0.02 and 0.004, respectively). Conclusions: Among neuronal VGCC-autoantibody–seropositive patients, autoimmune neurological phenotypes and cancer types are diverse. Cautious interpretation of results (particularly medium and low values) is advised. Muscle Nerve, 2016 Muscle Nerve 54: 220–227, 2016.

KW - ataxia

KW - calcium channel

KW - myasthenia

KW - neuropathy

KW - paraneoplastic

UR - http://www.scopus.com/inward/record.url?scp=84978910648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978910648&partnerID=8YFLogxK

U2 - 10.1002/mus.25027

DO - 10.1002/mus.25027

M3 - Article

C2 - 26789908

AN - SCOPUS:84978910648

SN - 0148-639X

VL - 54

SP - 220

EP - 227

JO - Muscle and Nerve

JF - Muscle and Nerve

IS - 2

ER -